Cost-effectiveness analysis shows rimegepant as the best option for acute migraine treatment, suggesting it is suitable for low-frequency migraine patients.
Ubrogepant, rimegepant, and zavegepant are not cost-effective options for acute migraine treatment but may be appropriate for patients experiencing 2 or fewer migraines per month. If a gepant is to be prescribed, rimegepant is the most cost-effective option of the 3.
No takes yet. Share an insight, caveat, or question.
Gokhale et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: